Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > A couple of "stupid" questions

<< Previous

Bullboard Posts

Next >>

Post by woundedkneeon Apr 23, 2021 1:28pm

413 Views

Post# 33055947

A couple of "stupid" questions

This almalgamation looks like a good idea to me, but saying that does anyone know if there is any new shares issued in this transaction?(dilution) And I feel foolish asking this, but we have proven safety, effacy, and to a great degree the dosage in P2, so what does P3 add to this and what are the circumstances during p3 trials that we should worry about? good weekend all

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects